Impact Biomedical Inc. Files 8-K for Material Agreement
Ticker: IBO · Form: 8-K · Filed: Sep 17, 2024 · CIK: 1834105
| Field | Detail |
|---|---|
| Company | Impact Biomedical Inc. (IBO) |
| Form Type | 8-K |
| Filed Date | Sep 17, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $3.00, $3,764,500.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, 8-k
TL;DR
IMPACT BIOMEDICAL INC. signed a big deal, filing an 8-K. Details TBD.
AI Summary
Impact Biomedical Inc. announced on September 16, 2024, that it entered into a material definitive agreement. The company also reported other events and filed financial statements and exhibits. The specific details of the agreement and the nature of the other events are not disclosed in this filing.
Why It Matters
This filing indicates a significant development for Impact Biomedical Inc., potentially involving new partnerships, acquisitions, or financial arrangements that could impact its future operations and stock performance.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement, which could be positive or negative depending on its terms, introducing uncertainty.
Key Players & Entities
- IMPACT BIOMEDICAL INC. (company) — Registrant
- September 16, 2024 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of incorporation
- 1400 Broadfield Blvd., Suite 130 Houston, TX 77084 (address) — Principal executive offices
- (585) 325-3610 (phone_number) — Registrant's telephone number
FAQ
What is the nature of the material definitive agreement entered into by Impact Biomedical Inc.?
The filing does not disclose the specific terms or nature of the material definitive agreement.
When was the material definitive agreement entered into?
The material definitive agreement was entered into on September 16, 2024.
What other items are reported in this 8-K filing besides the material agreement?
The filing also reports 'Other Events' and 'Financial Statements and Exhibits'.
Where is Impact Biomedical Inc. headquartered?
Impact Biomedical Inc.'s principal executive offices are located at 1400 Broadfield Blvd., Suite 130, Houston, TX 77084.
What is the company's state of incorporation?
The company is incorporated in Nevada.
Filing Stats: 1,040 words · 4 min read · ~3 pages · Grade level 12 · Accepted 2024-09-17 17:18:29
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share N/A N/A Indic
- $3.00 — Stock"), at a public offering price of $3.00 per share. The Ordinary Shares were off
- $3,764,500.00 — lowance and expenses, was approximately $3,764,500.00. A final prospectus relating to this Of
Filing Documents
- form8-k.htm (8-K) — 46KB
- ex1-1.htm (EX-1.1) — 43KB
- ex99-1.htm (EX-99.1) — 9KB
- ex99-2.htm (EX-99.2) — 11KB
- ex1-1_001.jpg (GRAPHIC) — 401KB
- ex1-1_002.jpg (GRAPHIC) — 418KB
- ex1-1_003.jpg (GRAPHIC) — 529KB
- ex1-1_004.jpg (GRAPHIC) — 596KB
- ex1-1_005.jpg (GRAPHIC) — 554KB
- ex1-1_006.jpg (GRAPHIC) — 526KB
- ex1-1_007.jpg (GRAPHIC) — 566KB
- ex1-1_008.jpg (GRAPHIC) — 592KB
- ex1-1_009.jpg (GRAPHIC) — 577KB
- ex1-1_010.jpg (GRAPHIC) — 545KB
- ex1-1_011.jpg (GRAPHIC) — 471KB
- ex1-1_012.jpg (GRAPHIC) — 432KB
- ex1-1_013.jpg (GRAPHIC) — 428KB
- ex1-1_014.jpg (GRAPHIC) — 426KB
- ex1-1_015.jpg (GRAPHIC) — 496KB
- ex1-1_016.jpg (GRAPHIC) — 495KB
- ex1-1_017.jpg (GRAPHIC) — 522KB
- ex1-1_018.jpg (GRAPHIC) — 524KB
- ex1-1_019.jpg (GRAPHIC) — 509KB
- ex1-1_020.jpg (GRAPHIC) — 465KB
- ex1-1_021.jpg (GRAPHIC) — 627KB
- ex1-1_022.jpg (GRAPHIC) — 593KB
- ex1-1_023.jpg (GRAPHIC) — 563KB
- ex1-1_024.jpg (GRAPHIC) — 338KB
- ex1-1_025.jpg (GRAPHIC) — 454KB
- ex1-1_026.jpg (GRAPHIC) — 479KB
- ex1-1_027.jpg (GRAPHIC) — 336KB
- ex1-1_028.jpg (GRAPHIC) — 409KB
- ex1-1_029.jpg (GRAPHIC) — 192KB
- ex1-1_030.jpg (GRAPHIC) — 79KB
- ex1-1_031.jpg (GRAPHIC) — 65KB
- ex1-1_032.jpg (GRAPHIC) — 45KB
- ex1-1_033.jpg (GRAPHIC) — 68KB
- ex1-1_034.jpg (GRAPHIC) — 75KB
- ex1-1_035.jpg (GRAPHIC) — 53KB
- ex1-1_036.jpg (GRAPHIC) — 469KB
- ex1-1_037.jpg (GRAPHIC) — 580KB
- ex1-1_038.jpg (GRAPHIC) — 161KB
- ex1-1_039.jpg (GRAPHIC) — 105KB
- ex1-1_040.jpg (GRAPHIC) — 115KB
- ex1-1_041.jpg (GRAPHIC) — 251KB
- ex1-1_042.jpg (GRAPHIC) — 481KB
- ex1-1_043.jpg (GRAPHIC) — 542KB
- ex1-1_044.jpg (GRAPHIC) — 618KB
- ex1-1_045.jpg (GRAPHIC) — 626KB
- ex1-1_046.jpg (GRAPHIC) — 522KB
- ex1-1_047.jpg (GRAPHIC) — 625KB
- ex1-1_048.jpg (GRAPHIC) — 439KB
- ex1-1_049.jpg (GRAPHIC) — 465KB
- ex1-1_050.jpg (GRAPHIC) — 171KB
- ex1-1_051.jpg (GRAPHIC) — 36KB
- ex1-1_052.jpg (GRAPHIC) — 253KB
- ex1-1_053.jpg (GRAPHIC) — 113KB
- ex99-1_001.jpg (GRAPHIC) — 35KB
- ex99-2_001.jpg (GRAPHIC) — 22KB
- 0001493152-24-036888.txt ( ) — 29322KB
- ibo-20240916.xsd (EX-101.SCH) — 3KB
- ibo-20240916_lab.xml (EX-101.LAB) — 33KB
- ibo-20240916_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. IMPACT BIOMEDICAL INC. Date: September 17, 2024 By: /s/ Frank D. Heuszel Name: Frank D. Heuszel Title: Chief Executive Officer